Reinforcement learning in treatment pathway optimization: A case study in oncology

Optimizing treatment pathways in oncology is a complex challenge due to the dynamic nature of cancer progression, patient-specific variability, and the multitude of available therapeutic options. Traditional decision-making frameworks often rely on static guidelines that may not account for real-time patient responses or evolving clinical evidence. Reinforcement learning (RL), a branch of machine learning, offers a promising approach to address this challenge by enabling personalized and adaptive treatment strategies. Unlike conventional methods, RL models learn optimal decision-making policies by interacting with patient data and maximizing cumulative outcomes over time. In oncology, RL algorithms have been applied to optimize chemotherapy regimens, radiation therapy schedules, and immunotherapy combinations. By leveraging historical patient records, genomic profiles, and real-time clinical data, RL models can predict treatment outcomes and suggest pathways tailored to individual patients. For example, deep Q-networks and policy gradient methods have demonstrated potential in dynamically adjusting treatment plans based on tumour response, reducing toxicity, and improving survival rates. This study presents a case-based exploration of RL application in oncology, highlighting the development and validation of RL-driven models for personalized cancer care. While RL shows significant promise, its implementation faces challenges such as data sparsity, computational complexity, and the need for interpretability in clinical decision-making. Furthermore, ethical considerations, including ensuring fairness and mitigating bias in algorithms, remain critical. By addressing these challenges through interdisciplinary collaboration and robust validation frameworks, RL can revolutionize oncology treatment planning, paving the way for more precise, patient-centreed care.